Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.
The transcriptional activity of the androgen receptor (AR) is regulated by both ligand binding and post-translational modifications, including acetylation and small ubiquitin-like modifier (SUMO)ylation. Histone deacetylases (HDACs) are known to catalyze the removal of acetyl groups from both histones and non-histone proteins. In this study, we report that HDAC4 binds to and inhibits the activity of the AR. This inhibition was found to depend on the SUMOylation, instead of deacetylation, of the AR. Consistently, HDAC4 increases the level of AR SUMOylation in both whole-cell and cell-free assay systems, raising the possibility that the deacetylase may act as an E3 ligase for AR SUMOylation. Knock down of HDAC4 increases the activity of endogenous AR and androgen induction of prostate-specific antigen expression and prostate cancer cell growth, which is associated with decreased SUMOylation of the receptor. Overall, the studies identify HDAC4 as a positive regulator for AR SUMOylation, revealing a deacetylase-independent mechanism of HDAC action in prostate cancer cells.
Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL 33612-4799, USA.
Y
Y
Yang
A K-W
AK
Tse
P
P
Li
Q
Q
Ma
S
S
Xiang
S V
SV
Nicosia
E
E
Seto
X
X
Zhang
W
W
Bai
D000726:Androgen Antagonists / Q000494:pharmacology*; D001483:Base Sequence; D055162:Biocatalysis; D045744:Cell Line, Tumor; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D011944:Receptors, Androgen / Q000187:drug effects* / Q000378:metabolism; D012097:Repressor Proteins / Q000378:metabolism*; D015398:Signal Transduction; D058207:Sumoylation
D000726:Androgen Antagonists; D017931:DNA Primers; D011944:Receptors, Androgen; D012097:Repressor Proteins; C400300:HDAC4 protein, human; D006655:Histone Deacetylases
EMBO J. 1999 Sep 15;18(18):5099-107
10487761
Mol Cell Biol. 2004 Jul;24(13):6021-8
15199155
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14145-50
11121022
Mol Endocrinol. 2009 Mar;23(3):292-307
19116244
Mol Cell Biol. 2004 Dec;24(24):10529-41
15572661
Cancer Cell. 2006 Oct;10(4):309-19
17045208
Science. 1995 Nov 24;270(5240):1354-7
7481822
Endocr Res. 1996 Aug;22(3):197-219
8875135
J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):307-13
10419007
Exp Cell Res. 2006 Oct 1;312(16):3165-83
16860317
Mol Endocrinol. 2002 Apr;16(4):661-73
11923464
Mol Cell Biol. 2006 Nov;26(21):8122-35
16923962
Curr Top Microbiol Immunol. 2003;274:237-68
12596910
Mol Cell Biol. 2003 Jan;23(1):104-18
12482965
Science. 1988 Apr 15;240(4850):327-30
3353727
Annu Rev Biochem. 1994;63:451-86
7979245
J Mol Endocrinol. 1999 Jun;22(3):313-25
10343290
J Biol Chem. 2002 Aug 16;277(33):30283-8
12060666
EMBO J. 2002 Jun 3;21(11):2682-91
12032081
Rev Endocr Metab Disord. 2002 Sep;3(3):185-92
12215713
Mol Cell. 2007 Jan 12;25(1):57-70
17218271
Biochem Biophys Res Commun. 2005 Jul 8;332(3):702-9
15907800
J Biol Chem. 2000 Jul 7;275(27):20853-60
10779504
Mol Endocrinol. 2007 Aug;21(8):1807-21
17505061
J Biol Chem. 1996 May 31;271(22):12801-6
8662804
Science. 1988 May 13;240(4854):889-95
3283939
J Biol Chem. 2002 Jul 19;277(29):25904-13
11994312
Mol Cell Biol. 2005 Mar;25(6):2273-87
15743823
Biochem Pharmacol. 2004 Sep 15;68(6):1199-208
15313417
J Biol Chem. 2004 Feb 27;279(9):8389-95
14670946
Prostate. 1998 Sep 1;36(4):256-63
9719026
Mol Cell Biol. 2004 Jun;24(12):5106-18
15169878
J Biol Chem. 2001 Jun 8;276(23):20444-50
11278645
Mol Endocrinol. 2004 Jan;18(1):13-25
14576337
Mol Endocrinol. 2000 Nov;14(11):1882-96
11075819
Mol Cell Biol. 2005 Oct;25(19):8456-64
16166628
J Biol Chem. 2002 Nov 1;277(44):41311-7
12177000
Mol Cell Biol. 1999 Feb;19(2):1182-9
9891052
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7211-5
3174628